文献速递神经肿瘤

经济有效的检测算法识别侵袭性、EGFR扩增的IDH野生型低级别弥漫性胶质瘤

Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
PubMed 文献 · Neuro Oncol · 2019-01-01

基于cIMPACT-NOW更新3对EGFR扩增的推荐,研究利用真实临床数据提出经济有效的诊断检测算法。在71例WHO II/III级胶质瘤中,EGFR扩增占28.2%,几乎均见于IDH野生型,且与更差的总体生存显著相关(P<0.0001)。

要点

  • 在71例WHO II/III级弥漫性胶质瘤中,EGFR扩增发生率为28.2%,除一例外均见于IDH野生型。
  • EGFR扩增提示更具侵袭性的肿瘤亚群,总体生存比较有显著差异(P<0.0001,log-rank)。
  • 先检测IDH、仅对IDH野生型行EGFR FISH的算法在本机构可降低约37.9%成本。

核心结论

  • EGFR扩增的弥漫性胶质瘤行为上呈「胶质母细胞瘤样」,可能代表采样不足的胶质母细胞瘤或固有侵袭性生物学的IDH野生型弥漫性胶质瘤亚群。
  • 先检测IDH再对IDH野生型行EGFR FISH是经济有效且临床相关的检测算法,适用于常规临床实践。

研究设计与样本

  • 研究纳入连续系列弥漫性胶质瘤以确定EGFR扩增的患病率、分布、神经影像学特征(VASARI)和预后相关性,并利用癌症基因组图谱(TCGA)公开数据验证。
  • 成本-效用分析比较三种策略:EGFR与IDH联合检测、基于IDH结果的EGFR检测、不检测EGFR。

主要发现

  • 在n=71例WHO II/III级胶质瘤中,EGFR扩增检出率为28.2%,除一例外所有EGFR扩增均发生于IDH野生型胶质瘤。
  • 总体生存比较显示EGFR扩增标示显著更具侵袭性的肿瘤亚群(P<0.0001,log-rank)。
  • EGFR扩增肿瘤的影像学表型包括弥散受限(15%,P=0.02)、>5%肿瘤对比增强(75%,P=0.016)和轻度(非明显)增强(P=0.016)。

关键数值与推荐

  • 提出的检测算法将EGFR荧光原位杂交(FISH)检测保留用于IDH野生型病例。

临床怎么用

  • 作者提出先检测IDH、仅对IDH野生型病例行EGFR FISH的检测算法,认为其经济有效且临床相关,适用于常规临床实践。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Update 3 of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) recognizes amplification of epidermal growth factor receptor (EGFR) as one important aberration in diffuse gliomas (World Health Organization [WHO] grade II/III). While these recommendations endorse testing, a cost-effective, clinically relevant testing paradigm is currently lacking. Here, we use real-world clinical data to propose a financially effective diagnostic test algorithm in the context of new guidelines. METHODS: To determine the prevalence, distribution, neuroradiographic features (Visually Accessible REMBRANDT Images [VASARI]), and prognostic relevance of EGFR amplification in lower-grade gliomas, we assembled a consecutive series of diffuse gliomas. For validation we included publicly available data from The Cancer Genome Atlas. For a cost-utility analysis we compared combined EGFR and isocitrate dehydrogenase (IDH) testing, EGFR testing based on IDH results, and no EGFR testing. RESULTS: In n = 71 WHO grade II/III gliomas, we identified EGFR amplification in 28.2%. With one exception, all EGFR amplifications occurred in IDH-wildtype gliomas. Comparison of overall survival showed that EGFR amplification denotes a significantly more aggressive subset of tumors (P < 0.0001, log-rank). The radiologic phenotype in the EGFR-amplified tumors includes diffusion restriction (15%, P = 0.02), >5% tumor contrast enhancement (75%, P = 0.016), and mild (not avid) enhancement (P = 0.016). The proposed testing algorithm reserves EGFR fluorescence in situ hybridization (FISH) testing for IDH-wildtype cases. Implementation would result in ~37.9% cost reduction at our institution, or about $1.3-4 million nationally. CONCLUSION: EGFR-amplified diffuse gliomas are "glioblastoma-like" in their behavior and may represent undersampled glioblastomas, or subsets of IDH-wildtype diffuse gliomas with inherently aggressive biology. EGFR FISH after IDH testing is a financially effective and clinically relevant test algorithm for routine clinical practice.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Bale TA, Jordan JT, Rapalino O, et al. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma. Neuro Oncol. 2019. PMID: 30496526. doi:10.1093/neuonc/noy201

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。